A new blood test analysing the folding of amino acids, rather than their amounts, shows promise in detecting the earliest biological signs of Alzheimer's disease, according to a recent study.
Scientists develop a blood test that detects Alzheimer’s by measuring protein structural changes rather than protein quantity.
Bristol-Myers Squibb (NYSE:BMY) and Evotec have advanced molecular glue candidate BMS-986506 into Phase 1 trials for clear cell renal cell carcinoma. The program marks the first clinical-stage asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results